Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp

State Street Corp grew its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 50.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,209,781 shares of the company’s stock after acquiring an additional 405,169 shares during the period. State Street Corp owned about 2.70% of Y-mAbs Therapeutics worth $15,909,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA raised its position in Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after purchasing an additional 2,760 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $44,000. China Universal Asset Management Co. Ltd. lifted its stake in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after acquiring an additional 3,589 shares during the period. Finally, FMR LLC grew its position in Y-mAbs Therapeutics by 23.1% in the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after acquiring an additional 6,822 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB opened at $8.15 on Wednesday. Y-mAbs Therapeutics, Inc. has a 1 year low of $6.48 and a 1 year high of $20.90. The company has a market capitalization of $365.03 million, a price-to-earnings ratio of -15.09 and a beta of 0.61. The business has a 50-day moving average of $12.11 and a two-hundred day moving average of $12.51.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the firm earned ($0.18) EPS. As a group, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on YMAB. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.